Edgestream Partners L.P. bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 22,184 shares of the medical equipment provider’s stock, valued at approximately $1,971,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Zimmer Biomet in the second quarter valued at about $1,344,282,000. State Street Corp lifted its stake in shares of Zimmer Biomet by 0.6% in the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock worth $766,343,000 after acquiring an additional 52,044 shares during the period. Primecap Management Co. CA acquired a new position in shares of Zimmer Biomet in the second quarter worth approximately $328,578,000. Dimensional Fund Advisors LP boosted its holdings in Zimmer Biomet by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after acquiring an additional 24,208 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in Zimmer Biomet during the 2nd quarter valued at approximately $187,480,000. 88.89% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Zimmer Biomet
In other Zimmer Biomet news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider directly owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The SEC filing for this sale provides additional information. Corporate insiders own 1.28% of the company’s stock.
Zimmer Biomet Stock Down 0.2%
Zimmer Biomet stock opened at $101.22 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.46 and a debt-to-equity ratio of 0.49. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $112.54. The firm’s fifty day moving average is $96.50 and its 200 day moving average is $92.96. The company has a market capitalization of $19.16 billion, a PE ratio of 25.62, a PEG ratio of 2.38 and a beta of 0.50.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.02. The firm had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.90 earnings per share. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.56 EPS for the current fiscal year.
Zimmer Biomet Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Wednesday, September 30th. Zimmer Biomet’s payout ratio is 24.30%.
Analysts Set New Price Targets
Several research analysts have issued reports on the stock. Wells Fargo & Company upgraded shares of Zimmer Biomet from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $113.00 to $123.00 in a report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Citigroup increased their price objective on shares of Zimmer Biomet from $99.00 to $117.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Royal Bank Of Canada lifted their target price on shares of Zimmer Biomet from $110.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Finally, Canaccord Genuity Group lifted their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research note on Monday, August 10th. Eight research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $114.32.
Get Our Latest Stock Report on ZBH
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.
Read More
- Five stocks we like better than Zimmer Biomet
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
